Company Filing History:
2 out of 4,770 
1 out of 43 
Years Active: 1998-2002
Title: The Innovations of Jeffrey Ulmer
Introduction
Jeffrey Ulmer is a notable inventor based in Chalfont, PA (US), recognized for his contributions to the field of biotechnology. He holds 2 patents that focus on innovative approaches to vaccine development, particularly in combating tuberculosis.
Latest Patents
Ulmer's latest patents include a polynucleotide tuberculosis vaccine. This innovative vaccine involves cloning genes encoding proteins into eukaryotic expression vectors to express these proteins in mammalian muscle cells in vivo. Animals are immunized through the injection of these DNA constructs, known as polynucleotide vaccines or PNV, into their muscles. The immune antisera produced against the antigens demonstrates specific T-cell responses in the spleen cells of vaccinated mice. The cytokine secretion profile in response to antigen 85 indicates a T 1 type of helper T-cell response, characterized by high levels of IL-2 and IFN-γ. The protective efficacy of this DNA vaccine was confirmed in mice after being challenged with BCG, showing a reduction in mycobacterial multiplication in the spleens and lungs of DNA-vaccinated mice compared to control groups.
Career Highlights
Throughout his career, Ulmer has worked with prominent companies such as Merck & Co., Inc. and N.V. Innogenetics S.A. His experience in these organizations has contributed significantly to his expertise in vaccine development and biotechnology.
Collaborations
Some of his notable coworkers include Jean Content and Kris Huygen, who have collaborated with him on various projects in the field of vaccine research.
Conclusion
Jeffrey Ulmer's innovative work in developing polynucleotide vaccines showcases his commitment to advancing medical science and improving public health. His contributions are vital in the ongoing fight against infectious diseases like tuberculosis.